BMC Cancer (Apr 2019)
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
- Aleksandar Sekulic,
- Michael R. Migden,
- Nicole Basset-Seguin,
- Claus Garbe,
- Anja Gesierich,
- Christopher D. Lao,
- Chris Miller,
- Laurent Mortier,
- Dedee F. Murrell,
- Omid Hamid,
- Jorge F. Quevedo,
- Jeannie Hou,
- Edward McKenna,
- Natalie Dimier,
- Sarah Williams,
- Dirk Schadendorf,
- Axel Hauschild,
- for the ERIVANCE BCC Investigators
Affiliations
- Aleksandar Sekulic
- Mayo Clinic Scottsdale, 13400 East Shea Boulevard
- Michael R. Migden
- Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center
- Nicole Basset-Seguin
- Service de Dermatologie, Hôpital Saint-Louis
- Claus Garbe
- Studienzentrum Dermatologische Onkologie, Universitätsklinikum Tübingen
- Anja Gesierich
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg
- Christopher D. Lao
- University of Michigan
- Chris Miller
- Department of Dermatology, University of Pennsylvania Medical Center
- Laurent Mortier
- Clinique de Dermatologie, Hôpital Claude Huriez
- Dedee F. Murrell
- Dermatology Department, St George Clinical School, University of New South Wales
- Omid Hamid
- The Angeles Clinic and Research Institute
- Jorge F. Quevedo
- Mayo Clinic
- Jeannie Hou
- Genentech, Inc.
- Edward McKenna
- Genentech, Inc.
- Natalie Dimier
- Roche Products Limited
- Sarah Williams
- Roche Products Limited
- Dirk Schadendorf
- Klinikum für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen
- Axel Hauschild
- Universitätsklinikum Schleswig-Holstein
- for the ERIVANCE BCC Investigators
- DOI
- https://doi.org/10.1186/s12885-019-5568-6
- Journal volume & issue
-
Vol. 19,
no. 1
pp. 1 – 1
Abstract
Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:
